Use of Hormone Replacement Therapy by Postmenopausal Women After Publication of the Women's Health Initiative Trial
Open Access
- 1 April 2005
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journals of Gerontology: Series A
- Vol. 60 (4) , 460-462
- https://doi.org/10.1093/gerona/60.4.460
Abstract
Background. After publication of the Women's Health Initiative (WHI) trial in July 2002, many physicians discontinued hormone replacement therapy (HRT) in most of their postmenopausal patients. However, little is known about the women who remain on HRT. Methods. We performed a retrospective chart analysis of 1000 postmenopausal women seen at an internal medicine practice to establish the prevalence of continued HRT use after publication of the WHI trial, determine the reasons for its use, and establish the prevalence of conditions adversely affected by HRT. Results. Of 1000 postmenopausal women, mean age 66 ± 9 years, 445 (45%) had used or still were on HRT (HRT users) at the time of the review. Of 445 HRT users, 159 (36%) were still on HRT, whereas 286 women (64%) had discontinued therapy. Of the latter, 181 women (63%) had stopped using HRT after the WHI publication, and 136 women (48%) reported the study as the direct cause of HRT cessation. Of the 159 women still on HRT, the main reasons for continued use were severe menopausal symptoms in 39 women (25%), osteoporosis or osteopenia in 31 women (20%), and patient preference in 20 women (13%). Of the 159 women still on HRT, 41 had atherosclerotic disease (26%), 7 had previous venous thromboembolic disease (4%), 8 had a history of breast cancer (5%), and 12 had a family history of breast cancer (8%). Conclusions. Despite the widespread impact of the WHI trial results, many women still remained on HRT in an internal medicine practice for a variety of reasons and despite relative contraindications to its use.Keywords
This publication has 14 references indexed in Scilit:
- Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapyObstetrics & Gynecology, 2003
- Changes in use of hormone replacement therapy after the report from the Women's Health Initiative: cross sectional survey of usersBMJ, 2003
- Effects of Estrogen Plus Progestin on Risk of Fracture and Bone Mineral DensityThe Women's Health Initiative Randomized TrialJAMA, 2003
- Estrogen plus Progestin and the Risk of Coronary Heart DiseaseNew England Journal of Medicine, 2003
- Prescriptions for Estrogen Replacement Therapy in Ontario Before and After Publication of the Women's Health Initiative StudyJAMA, 2003
- Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal WomenJAMA, 2003
- Effect of Estrogen Plus Progestin on Stroke in Postmenopausal WomenJAMA, 2003
- Estrogen Plus Progestin and the Incidence of Dementia and Mild Cognitive Impairment in Postmenopausal WomenJAMA, 2003
- Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled TrialJAMA, 2002
- Randomized Trial of Estrogen Plus Progestin for Secondary Prevention of Coronary Heart Disease in Postmenopausal WomenJAMA, 1998